Clinical trial · Interventional
ctDNA Guided Treatment of Early Resistance to Targeted Treatment
Track and Treat in NSCLC (TATIN) - ctDNA Guided Treatment of Early Resistance to Targeted Treatment in Patients With EGFR Positive NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current strategy is to test for treatment resistance at the time of radiological progression and design subsequent treatment based on the mechanism of resistance. However, upon disease progression patients tend to deteriorate quickly and 30% - 40% of patients will not be in the clinical condition to receive next line treatment. Therefore, there is a potential for early resistance identification and directing treatment against it in order to improve patient outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ctDNA blood sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Osimertinib and Crizotinib
- description
- Osimertinib will be administered according to label: 80 mg once daily. Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily.
- interventionNames
- Diagnostic Test: ctDNA blood sample
Primary outcomes (1)
- measure
- percentage of patients in which a drug resistant clone can be detected with ctDNA
- timeFrame
- Trough study completion, an average of 2 years
- description
- To identify the percentage of patients in which a drug resistant clone can be detected with ctDNA before the emergence of radiological progression.
Secondary outcomes (1)
- measure
- the success rate of crizotinib and osimertinib combination treatment to eliminate MET amplification
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed metastatic NSCLC, characterized by a sensitizing exon 19 deletion or exon 21 L858R EGFR mutation. 2. WHO performance status 0-2. 3. Eligible for osimertinib treatment according to the label and according to the treating physician. 4. Patients must be ≥18 years of age. Exclusion Criteria: 1\. Patients with symptomatic central nervous system metastases who are neurologically unstable. Unstable brain metastases except for those who have completed definitive therapy and have had a stable neurological status for 2 weeks after completion of definitive therapy. Patients may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks prior to the start of study treatment and are clinically asymptomatic.
References
Publications (0)
Data not yet available